Form 4: Cocrystal Pharma Co-CEO Granted Stock Options

Cocrystal Pharma's Co-CEO and CFO, James Joseph Martin, was granted 49,229 non-qualified stock options with an exercise price of $1.1, vesting over time.

Summary

• James Joseph Martin, Co-CEO and CFO of Cocrystal Pharma, Inc. (COCP), was granted 49,229 non-qualified stock options.
• The stock options have an exercise price of $1.1 per share.
• The grant date for these options was January 9, 2026.
• The options were issued under the Issuer's 2025 Equity Incentive Plan.
• The vesting schedule dictates that one-half of the options will vest and become exercisable on January 9, 2027.
• The remaining half will vest and become exercisable in eight equal quarterly installments, commencing on March 31, 2027.
• Vesting is contingent upon the reporting person continuing to serve as an officer of the Issuer on each applicable vesting date.
• The non-qualified stock options are set to expire on January 9, 2036.
• The grant was approved by the Compensation Committee of the Board of Directors and is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns executive interests with shareholder value and is a routine, well-governed compensation event, indicating stability in executive incentives.

Positives

• The grant of stock options aligns the Co-CEO and CFO's interests with those of shareholders, incentivizing long-term performance and value creation.
• The approval of the options by the Compensation Committee of the Board of Directors indicates adherence to corporate governance best practices for executive compensation.

Risks

• The vesting of the non-qualified stock options is subject to the reporting person continuing to serve as an officer of the Issuer on each applicable vesting date, posing a risk of forfeiture if employment ceases before full vesting.

Future Outlook

The vesting schedule for the stock options, extending through quarterly installments commencing in March 2027, indicates a long-term commitment and incentive structure for the Co-CEO and CFO, aligning their future performance with shareholder value over several years.

Management Comments

• The grant of non-qualified stock options was approved by the Issuer's Compensation Committee of the Board of Directors, reflecting a strategic decision regarding executive incentives.

Industry Context

The grant of stock options to a key executive is a standard practice in the biotechnology and pharmaceutical industry, often used to attract, retain, and motivate top talent by aligning their financial interests with the long-term success and stock performance of the company. This type of compensation is particularly common in growth-oriented sectors where equity upside is a significant incentive.

Comparison to Industry Standards

• Executive equity compensation, such as stock option grants, is a widely adopted practice across the pharmaceutical and biotechnology sectors, comparable to compensation structures at companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity to incentivize leadership.
• The vesting schedule, with a portion vesting after one year and the remainder quarterly, is a common structure designed to encourage long-term retention and sustained performance, similar to plans observed at many publicly traded biotech firms.
• The exercise price of $1.1, which is likely the market price on the grant date, is standard for non-qualified stock options, ensuring that the executive benefits only if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of the Co-CEO and CFO with shareholders by incentivizing an increase in the company's stock price over the long term.
• Employees: This executive compensation may set a precedent or reflect the company's overall approach to performance-based incentives, potentially influencing broader employee motivation and retention strategies.

Next Steps

• The Co-CEO and CFO will continue to serve in their role to meet the vesting conditions for the stock options.
• The first half of the options will become exercisable on January 9, 2027.
• The remaining half of the options will begin vesting in quarterly installments starting March 31, 2027.

Key Dates

Keywords

Cocrystal Pharma, COCP, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Biotechnology